Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia

TA663 Final stakeholder list (PDF 184 KB)

TA663 Final scope (PDF 224 KB)

TA663 Final draft guidance (PDF 303 KB)

TA663 FDG Committee papers (PDF 6.58 MB)

TA663 Equality impact assessment (scoping) (PDF 128 KB)

Final draft guidance

Final draft guidance (PDF 127 KB)

Committee papers (PDF 6.17 MB)

Final scope (PDF 186 KB)

Final stakeholder list (PDF 137 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 210 KB)

Draft scope post referral (PDF 159 KB)